As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on ...
Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback